Table 1. Patient characteristics (n=1149).
| AC/FACa, n=434 (%) | Folfox/Folfirib, n=196 (%) | Carboplatin/Gemcitabinec, n=245 (%) | Capecitabined, n=274 (%) | |
|---|---|---|---|---|
| Age, years (median, range) |
52 (35–75) |
58 (26–81) |
58 (28–79) |
60 (28–82) |
|
Gender | ||||
| Male | 2 (0.05) | 113 (58) | 126 (51) | 108 (39) |
| Female |
432 (99.5) |
83 (42) |
119 (49) |
166 (61) |
|
Race | ||||
| Chinese | 278 (64) | 163 (83) | 180 (74) | 195 (71) |
| Malay | 74 (17) | 14 (7) | 37 (15) | 29 (11) |
| Indian | 32 (7) | 8 (4) | 8 (3) | 11 (4) |
| Others |
50 (12) |
11 (6) |
20 (8) |
39 (14) |
|
Tumour type | ||||
| Breast | 434 (100) | 0 | 60 (24) | 127 (46) |
| – Adjuvant | 363 (84) | 0 | 0 (0) | 0 (0) |
| – Metastatic |
71 (16) |
0 |
60 (24) |
127 (46) |
| Colon | 0 | 162 (83) | 0 (0) | 112 (41) |
| – Adjuvant | 0 | 76 (39) | 0 (0) | 71 (26) |
| – Metastatic |
0 |
86 (44) |
0 (0) |
41 (15) |
| Lung |
0 |
0 (0) |
110 (45) |
0 (0) |
| Others |
0 |
24 (17) |
75 (31) |
25 (13) |
| Use of steroids in pre-medication |
434 (100) |
196 (100) |
245 (100) |
0 (0) |
| HBV screen |
220 (51) |
68 (35) |
78 (32) |
82 (30) |
| Screen positive | 6/220 (3) | 10/68 (15) | 5/78 (7) | 9/82 (11) |
a
FAC: Fluorouracil 500 mg m−2, Doxorubicin 50 mg m−2 and Cyclophosphamide 500 mg m−2 every 3 weeks. AC: Doxorubicin 60 mg m−2 and Cyclophosphamide 600 mg m−2 every 3 weeks.
b
Folfox/Folfiri: Oxaliplatin 85 mg m−2 or Irinotecan 180 mg m−2+Folinic acid 400 mg m−2, Fluorouracil bolus 400 mg m−2, then 2400 mg m−2 as an infusion over 46 h every 2 weeks.
c
Carbo/Gem: Carboplatin (area under the concentration time curve 5), Gemcitabine 1000 mg m−2 day 1, day 8 every 3 weeks.
d
Capecitabine: Capecitabine 1000–1250 mg m−2 days 1–14 every 3 weeks.